Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 2013. The report focuses on the announcement of top-line results from the pivotal Phase III STABILITY trial evaluating the investigational drug darapladib for chronic coronary heart disease (CHD). Darapladib is an Lp-PLA2 inhibitor and is not currently approved for use anywhere in the world.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report is a clinical trial update rather than a financial earnings release.
Material Changes and Clinical Results
- Primary Endpoint Failure: The STABILITY trial did not meet its primary endpoint. The study measured time to first occurrence of any major adverse cardiovascular event (MACE), defined as myocardial infarction, stroke, or cardiovascular death.
- Statistical Outcome: The trial showed a relative risk reduction of 6% with a p-value of 0.199, which was not statistically significant.
- Secondary Endpoints: There were greater reductions in some pre-defined secondary endpoints (nominal p<=0.05), though these require further analysis.
- Safety Profile: The overall safety profile showed no major imbalance in serious adverse events between the active and placebo groups. Frequently reported adverse events included diarrhoea and odour, occurring at frequencies similar to Phase II trials.
Outlook, Management Commentary, and Risks
Patrick Vallance, President of Pharmaceuticals R&D, stated that GSK will continue to investigate the role of Lp-PLA2 inhibition. Management plans to better understand the data, including patient sub-group evaluations, and await the outcome of the second Phase III study, SOLID-TIMI 52, which evaluates darapladib in acute coronary syndrome. The SOLID-TIMI 52 trial is ongoing, has enrolled over 13,000 patients, and is expected to complete in 2014. Full results of the STABILITY study are scheduled for presentation at a scientific meeting in 2014.
Risks and Contingencies: The filing includes a cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties described in the company's 2012 Annual Report on Form 20-F.
Key Facts for Investor Verification
- Verify the final analysis of secondary endpoints from the STABILITY trial.
- Monitor the progress and expected completion date of the SOLID-TIMI 52 trial (expected 2014).
- Confirm the regulatory strategy for darapladib following the primary endpoint miss in STABILITY.
- Review the 2012 Form 20-F for detailed risk factors affecting GSK's operations.